Evidence map›Paper›PMID 26980339›Full record

ReviewEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2016

Antileukotrienes in adenotonsillar hypertrophy: a review of the literature.

Murat Kar, Niyazi Altıntoprak, Nuray Bayar Muluk, Seckin Ulusoy, Sameer Ali Bafaqeeh, Cemal Cingi

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Haematologic Markers and Tonsil-to-Body Weight Ratio to Assist Adenotonsillar Hypertrophy Diagnosis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022
    Article
  5. Article
  6. Article
  7. The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Murat KarENT Clinics, Kumluca State Hospital, Antalya, Turkey.
Niyazi AltıntoprakENT Clinics, Tuzla State Hospital, Istanbul, Turkey.
Nuray Bayar MulukDepartment of Otorhinolaryngology, Medical Faculty, Kirikkale University, Kirikkale, Turkey. nbayarmuluk@yahoo.com.
Seckin UlusoyENT Clinics, GOP Taksim Education and Research Hospital, Istanbul, Turkey.
Sameer Ali BafaqeehENT Department, King Saud University, Riyad, Saudi Arabia.
Cemal CingiDepartment of Otorhinolaryngology, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey.
Eskişehir Osmangazi University · TRKing Saud University · SAKırıkkale University · TRSivas State Hospital · TRTaksim German Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the use of antileukotrienes for treating adenotonsillar hypertrophy. We reviewed the current literature on the anatomy of adenotonsillar tissue, adenotonsillar hypertrophy/hyperplasia (and the associated pathophysiology and symptoms), and the effects of antileukotrienes used to treat adenotonsillar hypertrophy. Leukotrienes (LTs) are inflammatory mediators produced by a number of cell types, including mast cells, eosinophils, basophils, macrophages, and monocytes. There are several types (e.g., LTA4, LTB4, LTC4, LTD4, and LTE4). By competitive binding to the cysLT1 receptor, LT-receptor antagonist drugs such as montelukast, zafirlukast, and pranlukast block the effects of cySHLTs, improving the symptoms of some chronic respiratory diseases. High numbers of LT receptors have been found in the tonsils of children with obstructive sleep apnea. Antileukotrienes reduce the apnea-hypopnea index and adenotonsillar inflammation. Antileukotrienes may be useful for children with adenotonsillar hypertrophy due to their anti-inflammatory effects, which help to reduce adenotonsillar inflammation.

Indexed as

AdenoidsHumansHypertrophyInflammationLeukotriene AntagonistsPalatine TonsilReceptors, LeukotrieneLeukotriene AntagonistsReceptors, LeukotrieneAdenotonsillar hypertrophyAnti-inflammatoryAntileukotrienesLeukotrienes

Identifiers

PMID26980339
OpenAlexW2298849563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.